Cancer-associated venous thromboembolism: A practical review beyond low-molecular-weight heparins

15Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.

Abstract

Patients with cancer are at significantly higher risk of developing, and dying from, venous thromboembolism (VTE). The CLOT trial demonstrated superiority of low-molecular-weight heparins (LMWH) over warfarin for recurrent VTE and established LMWH as the standard of care for cancer-associated VTE. However, with patients living longer with metastatic cancer, long-term injections are associated with significant cost and injection fatigue. Direct oral anticoagulants (DOACs) are an attractive alternative for treatment of cancer-associated VTE. Meta-analysis of subgroup data of patients with cancer from the large DOAC VTE trials and small non-randomized studies have found no difference in VTE recurrence or major bleeding. With this limited evidence, clinicians may decide to switch their patients who require long-term anticoagulation from LMWH to a DOAC. This requires careful consideration of the interplay between the patient's cancer and treatment course, with their underlying comorbidities.

Cite

CITATION STYLE

APA

Smrke, A., & Gross, P. L. (2017). Cancer-associated venous thromboembolism: A practical review beyond low-molecular-weight heparins. Frontiers in Medicine. Frontiers Media S.A. https://doi.org/10.3389/fmed.2017.00142

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free